



AMERICAN
UNIVERSITY OF BEIRUT
FACULTY OF MEDICINE

HEALTHCARE
PROFESSIONAL
DEVELOPMENT
CENTER



NAEF K. BASILE
CANCER INSTITUTE

BEST OF ASCO®
OFFICIALLY LICENSED

THE 21st BEST OF ASCO® THE 2026 ASCO ANNUAL MEETING


JULY 2026 | Beirut, Lebanon
10-11

Hybrid Meeting, Halim & Aida Daniel ACC Building
American University of Beirut Medical Center (AUBMC)

Best of ASCO Lebanon Chair:
Nagi S. El Saghir, MD, FACP, FASCO

BOA Lebanon Scientific Committee Chair
Hiba Moukadem, MD, MSc

Organized by AUBMC, Licensed by ASCO
In Collaboration with the Lebanese Society of Medical Oncology LSMO
and the Arab Medical Association Against Cancer AMAAC



WELCOME ADDRESS FROM THE PRESIDENT



Dear Colleagues and Friends,

It is my great pleasure to invite you again to our **Annual Best of ASCO® Lebanon Meeting** that we hold this year in HYBRID format. Speakers and Attendees in Lebanon will be in-person, speakers and attendees from overseas will be virtual.

The 2026 ASCO Annual Meeting is licensed by the American Society of Clinical Oncology (ASCO), and we will hold it Lebanon on **July 10 - 11, 2026** in HYBRID from the Daniel ACC Building Conference Rooms at the American University of Beirut Medical Center (AUBMC).

The 2026 ASCO Annual Meeting is organized by the Division of Hematology Oncology of the Department of Internal Medicine and the Naef K. Basile Cancer Institute (NKBCI) of the American University of Beirut Medical Center (AUBMC), in collaboration with Lebanese Society of Medical Oncology (LSMO) and Arab Medical Association Against Cancer (AMAAC)

Great advances in cancer research, practice-changing clinical trials and advances in patient management presented and discussed at ASCO26 in Chicago, IL, USA will be presented and discussed at Best of ASCO Lebanon. Presenters, Chairs, Discussants, and Attendees will have ample time for discussions and take-home messages.

Please note that Advance Registration is free and mandatory. Deadline for registration is July 9, 2026. All abstracts selected by Best of ASCO are enclosed in this brochure. Looking forward to a great meeting in Beirut, LB!

Nagi S. El Saghir, MD, FACP, FASCO

Professor of Clinical Medicine / Hematology Oncology

Director, Breast Center of Excellence,

Naef K. Basile Cancer Institute (NKBCI)

American University of Beirut Medical Center (AUBMC)

ns23@aub.edu.lb @NagiSaghir

IMPORTANT INFORMATIONS

ORGANIZED BY:

American University of Beirut Medical Center (AUBMC)

IN COLLABORATION WITH:

Lebanese Society of Medical Oncology (LSMO) and Arab Medical Association Against Cancer (AMAAC)

LICENSED BY:

The American Society of Clinical Oncology ASCO

BEST OF ASCO LEBANON PLANNING COMMITTEE:

Nagi S. El Saghir (President)

Hiba Moukadem (Chair)

Abir Ahmadiéh, MD

Arafat Tfayli, MD

Fadi Farhat, MD

George El Hachem, MD

Hady Ghanem, MD

Hala Kfoury, MD

Hampig Kourie, MD

Imane Abu Dalle, MD

Roland Eid, MD

Therese Abi Nasr, MD

Zeina Ayoub, MD

Speakers



Ahmad Ibrahim



Ahmad Younes



Arafat Tfayli



Aydah Al Awadi



Atlal Abu Sanad



Deborah Mukherji



Eileen O'Reily



Fadlo Khuri



Firas Kreidieh



Fadi Farhat



Giuseppe Curigliano



Ghassan Abou Alfa



Hikmat Abdelrazeq



Hiba Moukadem



Hamdy Abel Azim



Humaid Al Shamsi



Hampig kourie



Hala Kassouf



Hussein Tawbi



Hazem Assi



Issam Chehade



Issa Mohammad



Jean El Cheikh




Kayane Mheidly

Speakers



Kamal Al Rabi



Michael Wong



Meteb Al Foheidi



Marwan Ghosn



Marlene Chakhtoura



Matti Aapro



Malek Safa



Mahmoud El Tamer



Muhieddine Seoud



Mohamad Mohty



Michael Lontos



Nada Assaf



Nagi El Saghir



Ola Khorshid



Omalkhair Abukhair



Rana Yamout



Sally Temraz



Shereef Al Samany



Turki Al Faye'a



Toni Choueiri



Toufic Eid



Program / Friday, July 10, 2026

09:00 - 09:05 | Welcome Note: Nagi El Saghir, MD, FACP, FASCO

09:05 - 10:05 | HEMATOLOGIC MALIGNANCIES - LEUKEMIA, MYELODYSPLASTIC SYNDROMES AND ALLOTRANSPLANT, LYMPHOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Moderators: Imane Abou Dalle, MD - Nour Moukalled, MD - Khaled Ibrahim, MD - Ghid Amhaz, MD - Sami Khatib, MD

09:05 - 09:15 | **Abstract LBA6500** | Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial. **(First Author: John Mascarenhas, MD)** | Presented by Issam Shehadeh, MD

09:15 - 09:25 | **Abstract LBA7000** | frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). **(First Author: Georg Lenz, MD)** | Presented by Kayane Mheidly, MD

09:25 - 09:35 | **Abstract 7008** | Mediterranean CD19 genetic variations and potential influence on CAR T-cell therapy efficacy: Implications for population-tailored immunotherapy. **(First Author: Osama Alsmadi, MD)** | Presented by Jean El Cheikh, MD

09:35 - 09:45 | **Abstract LBA7506** | Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial. **(First Author: Paul Richardson, MD)** | Presented by Ahmad Ibrahim, MD

09:45 - 09:55 | **Abstract 7507** | MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator's choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM). **(First Author: Roberto Mina, MD)** | Presented by Mohamad Mohty, MD

09:55 - 10:05 | Discussion

Program / Friday, July 10, 2026

10:05 - 10:45

HEAD & NECK CANCERS

Moderators: Bassem Youssef, MD - Marc Murad, MD - Hassan Kanaan, MD - Ghazi Nsouli, MD

10:05 - 10:15

Abstract 6000 | Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).
(First Author: **Sudhir Nair, MD**)

Presented by
Issa Mohammad, MD

10:15 - 10:25

Abstract 6004 | Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.
(First Author: **Xiaoqing Wang, MD**)

Presented by
Arafat Tfayli, MD

10:25 - 10:35

Abstract 6008 | Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
(First Author: **Barbara Burtness, MD**)

Presented by
Malek Safa, MD

10:35 - 10:45

Discussion

10:45 - 11:00

COFFEE BREAK



Program / Friday, July 10, 2026

11:00 - 11:40

LUNG CANCER NON-SMALL CELL LOCAL-REGIONAL/SMALL CELL/OTHER THORACIC CANCERS

Moderators: Hassan Ghazal, MD - Imad Bu Akl, MD - Antoine Finianos, MD - Arafat Tfayli, MD

11:00 - 11:10

Abstract LBA3 | Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIa RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial
(First Author: **Jonathan Goldman, MD**)

Presented by
Fadlo Khuri, MD

11:10 - 11:20

Abstract 8000 | Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
(First Author: **Jamie Chافت, MD**)

Presented by
Fadlo Khuri, MD

11:20 - 11:30

Abstract 8004 | Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.
(First Author: **Brendan Heiden, MD**)

Presented by
Kamal Al Rabi, MD

11:30 - 11:40

Discussion

Program / Friday, July 10, 2026

11:40 - 12:20

LUNG CANCER NON-SMALL CELL METASTATIC

Moderators: Abir Ahmadieh, MD - Maroun Sadek, MD - Haifa Dbouk, MD - Lara Hilal, MD - Pierre Bou Khalil, MD

11:40 - 11:50

Abstract LBA4 | Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial. **(First Author: Chen Zhiwei, MD)**

**Presented by
Ola Khorshid, MD**

11:50 - 12:00

Abstract LBA8500 | Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
(First Author: John Heymach, MD)

**Presented by
Ahmad Younes, MD**

12:00 - 12:10

Abstract 8506 | Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
(First Author: Caicun Zhou, MD)

**Presented by
Turki Al Fayea, MD**

12:10 - 12:20

Discussion

12:20 - 13:00

OPENING CEREMONY



Program / Friday, July 10, 2026

12:20 - 13:00

OPENING CEREMONY

National Anthem

President, AUB

Fadlo Khuri, MD

H.E. Minister of Public Health

Rakan Nasreddine, MD

Chair, Scientific Planning Committee

Hiba Moukadem, MD

Head, Division of Hematology Oncology, AUBMC

Arafat Tfayli, MD

Director, Naef K. Basile Cancer Institute, AUBMC

Ali Taher, MD

Chair, Best of ASCO

Nagi El Saghir, MD

Master of Ceremony, Clinical Department Administrator, NKBCI

Ms. Nada Kashmar

Program / Friday, July 10, 2026

13:00 - 13:30

NON-CME NON-ASCO SATELLITE SYMPOSIUM SPONSORED BY JOHNSON & JOHNSON INNOVATIVE MEDICINE

Advancing EGFR-m NSCLC Treatment with Rybrevant

Presented by
Hazem Assi, MD

13:30 - 14:00

LUNCH BREAK

14:00 - 14:30

GASTROINTESTINAL CANCER - COLORECTAL AND ANAL

Moderators: Mohamad Khalife, MD - Layal Mahmasani, MD - Christina Khater, MD - Samer Dougham, MD

14:00 - 14:10

Abstract 102 | Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.
(First Author: Mitsuru Yokota, MD)

Presented by
Hampig Kourie, MD

14:10 - 14:20

Abstract LBA3503 | BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
(First Author: Scott Kopetz, MD)

Presented by
Humaid Al Shamsi, MD

14:20 - 14:30

Discussion



Program / Friday, July 10, 2026

14:30 - 15:00

GASTROINTESTINAL CANCER GASTROESOPHAGEAL, PANCREATIC, AND HEPATOBILIARY

Moderators: Fady Farhat, MD - Ali Shamseddine, MD - George Abi Saad, MD

14:30 - 14:40

Abstract LBA4000 | Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with embolization-eligible unresectable hepatocellular carcinoma (HCC). **(First Author: Ghassan Abou-Alfa, MD)**

**Presented by
Ghassan Abou-Alfa, MD**

14:40 - 14:50

Abstract LBA5 | Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study. **(First Author: Brian Wolpin, MD)**

**Presented by
Eileen O'Reilly, MD**

14:50 - 15:00

Discussion

15:00 - 15:30

BREAST CANCER LOCAL/REGIONAL/ADJUVANT

Moderators: Jaber Abbas, MD - Imad El-Hajj, MD - Zeina Ayoub, MD - Eman Sbaity, MD

15:00 - 15:10

Abstract 500 | First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. **(First Author: Robert Stein, MD)**

**Presented by
Shereef El Samany, MD**



Program / Friday, July 10, 2026

15:10 - 15:20	Abstract LBA503 Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial. <i>(First Author: Jana de Boniface, MD)</i>	Presented by Mahmoud El Tamer, MD
15:20 - 15:30	<i>Discussion</i>	
15:30 - 16:00	GENITOURINARY CANCER - KIDNEY AND BLADDER	
Moderators: Albert Hajj, MD - George Farha, MD - Raja Khauli, MD		
15:30 - 15:40	Abstract 4504 Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer. <i>(First Author: Nicholas James, MD)</i>	Presented by Toni Choueiri, MD
15:40 - 15:50	Abstract 4507 Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study. <i>(First Author: Thomas Powles, MD)</i>	Presented by Toni Choueiri, MD
15:50 - 16:00	<i>Discussion</i>	
16:00 - 16:15	COFFEE BREAK	

Program / Friday, July 10, 2026

16:15 - 16:45

NON-CME NON-ASCO SATELLITE SYMPOSIUM SPONSORED BY FATTAL/NOVARTIS

Recurrence Risk in Early Breast Cancer : the Role of CDK/6 inhibitors

Presented by
Marwan Ghosn, MD

16:45 - 17:30

UNRESTRICTED EDUCATIONAL GRANT SPONSORED BY ASTRA ZENECA

Redefining HER2 Expression: Latest Advances and Clinical Implications in HER2-Low and HER2-Ultralow Disease

Presented by
Naji El Saghir, MD

From Evidence to Practice: Real-World Case Discussions in HER2-Low and Ultra-Low Breast Cancer

Presented by
Fadi Farhat, MD

17:30 - 18:00

QUALITY CARE / PREVENTION

Moderator: Maya Roumani, MD

17:30 - 17:40

Abstract 12000 | Dexamethasone reduction or omission with NEPA and olanzapine for HEC
A phase III trial **(First Author: Jian Zhang, MD)**

Presented by
Matti Aapro, MD

17:40 - 17:50

Abstract LBA12003 | Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results. **(First Author: Luke Peppone, MD)**

Presented by
Rana Yamout, MD

17:50 - 18:00

Discussion

Program / Friday, July 10, 2026

18:00 - 18:50

MELANOMA SKIN CANCERS

Moderators: Said Saghie, MD - Ali Youssef, MD - Abdul Fattah Kheir, MD

18:00 - 18:10

Abstract LBA9503 | Darovasertib in combination with crizotinib versus investigator's choice as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma: Results from the phase 2/3 OptimUM-02 study. **(First Author: Marlana Orloff, MD)**

**Presented by
Hussein Tawbi, MD**

18:10 - 18:20

Abstract LBA9505 | Updated Outcomes from STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial: ECOG-ACRIN EA6174. **(First Author: Janice Mehnert, MD)**

**Presented by
Firas Kreidieh, MD**

18:20 - 18:30

Abstract 9518 | A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGYTE clinical trial. **(First Author: Michael Wong, MD)**

**Presented by
Michael Wong, MD**

18:30 - 18:40

Abstract LBA2 | SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. **(First Author: Mark Dickson, MD)**

**Presented by
Hazem Assi, MD**

18:40 - 18:50

Discussion



Program / Saturday, July 11, 2026

09:00 - 09:10		CNS	
Moderators: Saad Ayoubi, MD - Bassem Youssef, MD			
09:00 - 09:10	Abstract LBA2000 Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases. (First Author: Jeffrey Weinberg, MD)		Presented by Toufic Eid, MD
09:10 - 09:40		GYNECOLOGIC CANCERS	
Moderators: David Atallah, MD - Hiba Moukadem, MD			
09:10 - 09:20	Abstract 5505 CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer. (First Author: Gwenael Ferron, MD)		Presented by Muhieddine Seoud, MD
09:20 - 09:30	Abstract 5506 A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34). (First Author: Philipp Harter, MD)		Presented by Michael Lontos, MD
09:30 - 09:40	Discussion		



Program / Saturday, July 11, 2026

09:40 - 10:40

METASTATIC BREAST CANCER

Moderators: Roland Eid, MD - Nagi El Saghir, MD - Lobna Ezz El Arab, MD - Adel Tabshi, MD

09:40 - 09:50

Abstract 1004 | Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.
(First Author: Roger Von Moos, MD)

Presented by
Hikmat AbdelRazeq, MD

09:50 - 10:00

Abstract LBA1007 | First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the Phase III SERENA-6 trial.
(First Author: Francois Clement Bidard, MD)

Presented by
Giuseppe Curigliano, MD

10:00 - 10:10

Abstract 1005 | Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
(First Author: Erika Hamilton, MD)

Presented by
Hamdy Abdel Azim, MD

10:10 - 10:20

Abstract LBA1006 | Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2- LA/mBC): Primary analysis of the phase III persevERA BC trial. **(First Author: Nicholas Turner, MD)**

Presented by
Omalkhair Abulkhair, MD

10:20 - 10:30

Abstract LBA1000 | Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro. **(First Author: Kevin Kalinsky, MD)**

Presented by
Meteb Al Foheidi, MD

10:30 - 10:40

Discussion



Program / Saturday, July 11, 2026

10:40 - 10:55

COFFEE BREAK

10:55 - 11:25

NON-CME NON-ASCO SATELLITE SYMPOSIUM SPONSORED BY MSD

Triple-Negative Breast Cancer: Bridging Evidence and Real-World Practice

Presented by
Hiba Moukadem, MD

11:25 - 12:05

GENITOURINARY CANCER PROSTATE

Moderators: Mohamad Bulbul, MD - Ousama Mohamad, MD

11:25 - 11:35

Abstract LBA1 | Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. **(First Author: Mary-Ellen Taplin, MD)**

Presented by
Sally Temraz, MD

11:35 - 11:45

Abstract 5001 | Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study. **(First Author: Christopher Sweeney, MD)**

Presented by
Deborah Mukherji, MD

11:45 - 11:55

Abstract 108 | An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304). **(First Author: Sebastian R. Medina, MD)**

Presented by
Hala Kassouf, MD

11:55 - 12:05

Discussion



Program / Saturday, July 11, 2026

12:05 - 12:35

PREVENTION, RISK REDUCTION AND GENETICS

Moderators: David Wehbe, MD - Faysal Kak, MD

12:05 - 12:15

Abstract 10503 | Effect of type and location of BRCA2 deleterious variant on prognosis and survival in metastatic prostate cancer: A longitudinal, international, cohort study from hormone-sensitive to castration-resistant settings.
(First Author: Lorena Incorvaia, MD)

**Presented by
Nada Assaf, MD**

12:15 - 12:25

Abstract 10515 | Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.
(First Author: Andrea De Censi, MD)

**Presented by
Aydah Awadhi, MD**

12:25 - 12:35

Discussion

12:35 - 13:05

QUALITY CARE / HEALTH RESEARCH

Moderators: Hiba Moukadem, MD - Omayya Baydoun, MD

12:35 - 12:45

Abstract 11000 | The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.
(First Author: Salman Jajja, MD)

**Presented by
Marlene Chakhtoura, MD**



Program / Saturday, July 11, 2026


12:45 - 12:55	<i>Abstract 12010</i> Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial. (First Author: Jennifer A. Ligibel, MD)	Presented by Atlal Abu Sanad, MD
12:55 - 13:05	<i>Discussion</i>	
13:05	<i>Closing Remarks</i>	

فستال
Fattal



Johnson & Johnson
Innovative Medicine

AstraZeneca
What science can do



MSD



Holmed GROUP
Your Agile Healthcare Partner



Benta Pharma Industries

ORGANIZED BY:

INFO MED
Innovating | Executing | Networking

UAE | Lebanon | Kuwait | Iraq